Site name unknown, Hong Kong, 0

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
1	Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01096030
3	Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib)	Terminated	Closed	Sunitinib or Imatinib	NCT00372567